PDS Biotechnology Corp (PDSB) stock
Close on Nov 12, 2026Market cap $54.85MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $54.85M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$33.67M
- EPS, diluted
- -$0.65
- Free cash flow
- -$27.75M
- Book value per share
- -$0.06
- Diluted shares
- 56M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.02
- Open
- $0.98
- Day's range
- $0.92 – $1.02
- Volume
- 2,956,665
- Average volume (20 days)
- 5,962,397
- Beta (5 years)
- 2.19
- 52-week range
- $0.20 – $1.79
- RSI (14 days)
- 43.7
- Volatility (1 year)
- 177.0%
- Relative volume
- 0.16×
- WACC
- 15.8%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PDSB | S&P 500 | Difference | PDSB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -35.5% | -2.7% | −32.8 pts | ||
| 3 months | +305.0% | -1.7% | +306.7 pts | ||
| Year to date | +27.3% | +11.9% | +15.4 pts | ||
| 1 year | +1.7% | +12.0% | −10.3 pts | ||
| 3 years | -81.6% | +78.2% | −159.8 pts | -43.2% | +21.2% |
| 5 years | -91.4% | +73.2% | −164.7 pts | -38.8% | +11.6% |
| 10 years | -99.6% | +309.6% | −409.2 pts | -42.4% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PDS Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- Update
About PDS Biotechnology
Pharmaceutical Preparations
PDS Biotechnology Corporation is a clinical-stage immunotherapy company that develops targeted cancer and infectious disease immunotherapies. The company designs investigational therapies utilizing its proprietary Versamune T-cell-activating platform, both alone and combined with PDS01ADC, an antibody-drug conjugate fused with interleukin 12. It also develops the Infectimune platform to produce preventive vaccines directed against infectious pathogens. These platforms are engineered to stimulate polyfunctional CD4 helper and CD8 killer T cells, as well as disease-specific neutralizing antibodies, to combat malignancies and infectious agents.
Company profile, executives and historyPDS Biotechnology stock: common questions
What is PDS Biotechnology's stock price?
PDSB closed at $0.98 on Nov 12, 2026, down 3.92% on the day. Over the past 52 weeks it traded between $0.20 and $1.79.
What is PDS Biotechnology's market cap?
PDS Biotechnology was worth $54.85M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PDSB's P/E ratio?
PDS Biotechnology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.65), so it has no meaningful P/E ratio.
Does PDS Biotechnology pay a dividend?
No. PDS Biotechnology has not paid a cash dividend over the last twelve months.
When does PDS Biotechnology report earnings next?
PDS Biotechnology's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PDSB stock performed over the past year?
Including dividends, PDSB returned +1.7% over the past year, against +12.0% for the S&P 500.
How many PDSB shares are sold short?
4M shares were sold short at the latest FINRA report, 10.21% of the float, or 1.0 days of average trading volume.
Who are PDS Biotechnology's competitors?
Companies most similar to PDS Biotechnology by business, industry and size include IMNN, PHIO, PVCT, PRLD, APVO.
See a number that looks wrong?